Filing Flows › Companies › Black Diamond Therapeutics › Report card
Black Diamond Therapeutics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate4 of 4 reports beat the EPS estimate
Black Diamond Therapeutics (BDTX) beat the analysts' EPS estimate in 4 of its last 4 reports (100%), by +23.6% on average. Next report: Nov 9, 2026, analysts expect EPS −$0.06.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS |
|---|---|---|---|---|---|
| Q to Jun 2026 | Aug 5, 2026 | −$0.20 | −$0.17 | +15.0% | −$0.17 |
| Q to Mar 2026 | May 7, 2026 | −$0.21 | −$0.16 | +25.2% | −$0.16 |
| Q to Dec 2025 | Mar 16, 2026 | −$0.17 | −$0.14 | +19.9% | — |
| Q to Sep 2025 | Nov 6, 2025 | −$0.23 | −$0.15 | +34.3% | −$0.15 |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Black Diamond Therapeutics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.